Marinus van Oers
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research 9
- Hematology top 10%
- Multiple Myeloma Research and Treatments 6
- Pathology and Forensic Medicine top 10%
- Lymphoma Diagnosis and Treatment 6
-
- Immunodeficiency and Autoimmune Disorders 4
-
- Viral-associated cancers and disorders 2
-
- Advanced Breast Cancer Therapies 3
-
- Protein Degradation and Inhibitors 3
- Glycosylation and Glycoproteins Research 2
- Co-authors
- Arnon P. KaterThorsten ZenzFlorence CymbalistaStephan StilgenbauerJohn G. GribbenDavid GonzálezHartmut DöhnerPeter Hillmen
- Partner nations
- NetherlandsDenmarkUnited States
In The Last Decade
Marinus van Oers
17 papers receiving 320 citations
Peers
Comparison fields: 5 of 30
- Genetics 183
- Hematology 130
- Pathology and Forensic Medicine 137
- Immunology 88
- Oncology 100
Countries citing papers authored by Marinus van Oers
This map shows the geographic impact of Marinus van Oers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marinus van Oers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marinus van Oers more than expected).
Fields of papers citing papers by Marinus van Oers
This network shows the impact of papers produced by Marinus van Oers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marinus van Oers. The network helps show where Marinus van Oers may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Marinus van Oers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 10 | |
| 2 | 2018 | 9 | |
| 3 | 2018 | 1 | |
| 4 | 2018 | 8 | |
| 5 | SF3B1 mutations in CLL are associated with a defective DNAdamage response | 2014 | 1 |
| 6 | 2013 | 31 | |
| 7 | 2012 | 133 | |
| 8 | 2012 | 2 | |
| 9 | 2012 | 1 | |
| 10 | 2012 | 72 | |
| 11 | FINAL DONOR VERSUS NO DONOR COMPARISON OF NEWLY DIAGNOSED MYELOMA PATIENTES INCLUDED IN THE HOVON 50/54 STUDY | 2010 | 2 |
| 12 | 2009 | 4 | |
| 13 | 2008 | 10 | |
| 14 | 2008 | 11 | |
| 15 | 2004 | 8 | |
| 16 | 2002 | 20 | |
| 17 | 2002 | 2 |
About Marinus van Oers
Marinus van Oers is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine, having authored 17 papers that have together received 325 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (9 papers), Multiple Myeloma Research and Treatments (6 papers), Lymphoma Diagnosis and Treatment (6 papers), Immunodeficiency and Autoimmune Disorders (4 papers), Advanced Breast Cancer Therapies (3 papers), Protein Degradation and Inhibitors (3 papers), Viral-associated cancers and disorders (2 papers) and Glycosylation and Glycoproteins Research (2 papers). The work is most often cited by research in Genetics (183 citations), Hematology (130 citations) and Pathology and Forensic Medicine (137 citations). Marinus van Oers has collaborated with scholars based in Netherlands, Denmark and United States. Frequent co-authors include Arnon P. Kater, Thorsten Zenz, Florence Cymbalista, Stephan Stilgenbauer, John G. Gribben, David González, Hartmut Döhner, Peter Hillmen, Šárka Pospı́šilová and Barbara Eichhorst.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.